Stocks to Watch, April 29: IndusInd Bank, Bajaj Finserv, Bajaj Finance, Trent, Shoppers Stop, TVS Motor, UltraTech, Praj Industries

The GIFT NIFTY futures level at 07:47 AM suggests that the NIFTY50 index will open 42 points higher.

Its net profit stood at ₹156.75 crore in the year-ago period.

The total income rose to ₹18,291.63 crore in the January-March quarter of the last fiscal year from ₹13,327.05 crore in the corresponding period of the preceding year.

The net profit jumped to ₹1,225.81 crore in the last fiscal year from ₹147.99 crore in the 2023-24 financial year.

Its revenue from operations rose 17% in the fourth quarter of the financial year 2024-25 (Q4FY25) to ₹9,550 crore as against ₹8,168.84 crore in the year-ago period.

Revenue from operations increased 12.95% to ₹23,063.32 crore in the latest March quarter, compared to ₹20,418.94 crore in the corresponding period of the previous fiscal year.

Besides, the company's board has recommended a dividend of ₹77.50 per equity share, subject to approval at the annual general meeting.

The company posted a consolidated net profit of ₹310 crore a year ago.

The company's total income rose to ₹3,278 crore during the quarter from ₹2,841 crore in the same period a year ago.

The consolidated net profit in FY25 also rose to ₹2,001 crore from ₹1,260 crore in FY24.

The incident resulted in damage to certain ancillary equipment with no impact on the core manufacturing infrastructure at the Penicillin-G production facility located in Kakinada, the Hyderabad-based drug maker said in a regulatory filing.

Importantly, there were no injuries reported, it added.

Its net profit stood at ₹788.03 crore in the year-ago period.

Total income also fell to ₹1,213.33 crore in January-March 2024-25 from ₹1,558.56 crore a year ago, according to a regulatory filing.

The company had posted a profit of ₹28.36 crore in the January-March period a year ago, Greenply said in a regulatory filing.

Its revenue from operations was at ₹648.77 crore, up 8.16% in the March quarter. It was at ₹599.78 crore in the corresponding period a year ago.

The offering included ₹3,000 crore through five-year bonds at a coupon of 6.87% and ₹2,000 crore through 10-year bonds at a coupon of 6.86%, a company statement said.

According to the statement, the bond issuance witnessed an overwhelming response from market participants, reflecting strong investor confidence in the company’s robust financial position and growth prospects.

The deal is spread over five years, Sonata Software said in a statement.

"Sonata Software secures a USD 73 million AI-led digital modernisation deal with a leading US TMT company," the statement said. Sonata will establish a dedicated AI-enabled Modernisation Engineering Centre in India under the deal.

The company reported a PAT of ₹216 crore in the year-ago period.

Castrol India follows a calendar year (January to December) for financial reporting.

Its revenue from operations rose 7.3% to ₹1,422 crore year-on-year during the quarter as against ₹1,325 crore reported in the same quarter last financial year.

The company has received letters of intent from Rajesh Power Services Limited for the project under Dakshin Gujarat Vij Company Limited worth Rs 1,50,98,65,000 and Adani Electricity Mumbai Limited worth Rs 79,27,80,051 for the supply of power cables.

As part of the five-year partnership, Wipro will modernise Vorwerk’s IT infrastructure using its AI-powered infrastructure operations solution, according to a company statement.

The company did not divulge the value of the deal.

This involves integrating all business applications, IT infrastructure, and cybersecurity systems into a single monitoring platform, enhancing visibility across Vorwerk’s technology landscape. It aims to substantially improve operational efficiency and strengthen cyber-risk management.

The Kerala-based lender had earned a net profit of ₹151 crore in the year-ago period.

During the quarter, the bank's total income increased to ₹1,362 crore against ₹991 crore a year ago.

Asset quality of the bank deteriorated marginally with gross non-performing assets rising to 1.57% of gross advances as of March 31, 2025, from 1.47% at the end of March 2024.

The Mumbai-based lender had earned a net profit of ₹807 crore in the year-ago period.

During the quarter, the bank's total income increased to ₹10,433 crore from ₹9,699 crore a year ago.

Interest income grew to ₹8,619 crore from ₹8,337 crore earlier.

However, net interest income (NII) in the quarter declined to ₹3,399 crore from ₹3,541 crore.

Besides, the lender on Monday reported a nearly 24% year-on-year jump in consolidated net profit to ₹665.72 crore for the quarter ended March.

The state-owned lender’s bottom line stood at ₹537.86 crore in the corresponding quarter a year ago.

Consolidated total income for the period under review was around ₹8,136 crore, up from ₹6,984 crore a year ago, it said.

Net profit of ₹149 crore in January-March – the fourth quarter of the April 2024 to March 2025 fiscal year – compared with ₹165 crore earnings in the same period of the previous year.

Revenue from operations was up 15% at ₹1,448 crore.

The company had posted a PAT of ₹343 crore in the year-ago period, Nippon Life India Asset Management said in a regulatory filing.

Its revenue from operations jumped 21% to ₹566.5 crore during the quarter under review from ₹468.3 crore in the January-March period of the financial year 2023-24 (FY24).

It had logged a net profit of ₹164.3 crore in the year-ago period, according to a regulatory filing.

Revenue rose 15.9% to ₹1,528.3 crore during the quarter against ₹1,317.8 crore a year ago.

Sequentially, profit and revenue climbed 30.9% and 3.4%, respectively.

During the quarter under review, the net interest income (NII) grew 16.2% to ₹734 crore as against ₹632 crore in Q4 FY24.

The augmented collections efforts led to an improvement in the housing finance firm’s gross and net non-performing assets (NPA) to 1.08% and 0.69%, respectively, during the quarter.

"This approval authorises the company to export ibuprofen to the Chinese markets. Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) effective in relieving pain, reducing inflammation, and lowering fever," the filing added.